Brand and Other Names:Nipent, DCF, more...2Deoxycoformycin
- Classes: Antineoplastics, Antimetabolite
Dosing & Uses
Dosage Forms & Strengths
powder for injection
Peripheral T-cell lymphomas
Cutaneous T-Cell lymphoma
Chronic lymphocytic leukemia
Orphan indications sponsor
- SuperGen, Inc; 4140 Dublin Blvd, Suite 200; Dublin, CA 94568
Other Indications & Uses
Off-label: CLL, CML, cutaneous T-cell lymphoma
Safety & efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Abdominal pain (16%)
Upper respiratory infection (13%)
Immune hypersensitivity reaction (2-11% )
Neurotoxicity (1-11% )
Hyponatremia (<3% )
Renal failure (<3% )
Frequency Not Defined
Microangiopathic hemolytic anemia
Thrombotic thrombocytopenic purpura
Black Box Warnings
The drug should be administered under the supervision of an experienced cancer chemotherapy physician in a facility equipped to diagnose and manage complications
Do not exceed recommended doses. Nephrotoxicity, hepatotoxicity, CNS, and pulmonary toxicity occurred in phase 1 studies that used higher doses than recommended
Do not use with concurrent fludarabine because of increased risk of pulmonary toxicity
Concomitant fludarabine: risk of fatal pulmonary toxicity
Relative: active infections
Epilepsy, liver dz, bone marrow depression
Weigh risk/benefit for pts w/ infections
Withhold if elevated SCr, renal dysfunction
Withhold or discontinue if evidence of CNS toxicity
Pregnancy & Lactation
Pregnancy Category: D
Lactation: not known if excreted in breast milk, do not nurse
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Half-Life: 5.7 hr
Peak Plasma: 3.2-9.7 ng/mL
Protein Bound: 4%
Vd: 42 L
Clearance: 68 mL/min/sq.meter
Excretion: urine (30-90%)
Mechanism of Action
Inhibits adenosine deaminase -> incr dATP -> inhibits ribonucleotide reductase -> blocks DNA synthesis
Solution: D5W, NS, LR
Y-site: fludarabine, melphalan, ondansetron, paclitaxel, sargramostim
Reconstitute 10 mg in 5 mL SWI for a final concentration 2 mg/mL
May be given by bolus or diluted to 25-50 mL with D5W to reach a final concentration of 0.33-0.16 mg/mL
Give 500-1000 mL of D5/½NS before infusion & 500 mL postinfusion
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs